The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?
| العنوان: | The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? |
|---|---|
| المؤلفون: | Marianna Silletta, Annamaria Rauco, Alessandra Felici, Antonio Russo, Luca Galli, Giuseppe Procopio, Antonio Lugini, Elena Verzoni, Daniele Santini, Pierfilippo Crucitti, Alessandro Conti, Mimma Rizzo, Daniela Modica, Stefano Cascinu, Giuseppe Tonini, Camillo Porta, Giacomo Cartenì, Cinzia Ortega, Francesco Pantano, Roberto Iacovelli, Valentina Ballatore, Giovanni Schinzari, Matteo Santoni, Michele Milella, Francesco Maria Guida |
| المساهمون: | Pantano, F., Santoni, M., Procopio, G., Rizzo, M., Iacovelli, R., Porta, C., Conti, A., Lugini, A., Milella, M., Galli, L., Ortega, C., Guida, F., Silletta, M., Schinzari, G., Verzoni, E., Modica, D., Crucitti, P., Rauco, A., Felici, A., Ballatore, V., Cascinu, S., Tonini, G., Carteni, G., Russo, A., Santini, D., Guida, F. M. |
| المصدر: | PLoS ONE PLoS ONE, Vol 10, Iss 4, p e0120427 (2015) |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Blood Glucose, lcsh:Medicine, Blood Pressure, urologic and male genital diseases, Triglyceride, Body Mass Index, Antineoplastic Agent, chemistry.chemical_compound, Retrospective Studie, Renal cell carcinoma, lcsh:Science, Multidisciplinary, Kidney Neoplasm, Kidney Neoplasms, Survival Rate, Everolimu, Cholesterol, Disease Progression, Human, medicine.drug, Research Article, Adult, medicine.medical_specialty, Adolescent, Urology, Blood sugar, Antineoplastic Agents, Young Adult, Internal medicine, medicine, Carcinoma, Humans, Everolimus, Carcinoma, Renal Cell, Triglycerides, Neoplasm Staging, Retrospective Studies, Biochemistry, Genetics and Molecular Biology (all), business.industry, lcsh:R, Renal Cell, Biomarkers, Lipid Metabolism, Agricultural and Biological Sciences (all), Lipid metabolism, Biomarker, medicine.disease, renal, carcinoma, Blood pressure, Endocrinology, chemistry, Pharmacodynamics, lcsh:Q, business |
| الوصف: | Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T and C +T raises were significantly associated with baseline BMI (p=0.0412, 0.0283 and 0.0001). Median TTP was significantly longer in patients with T raise compared to patients without T (10 vs 6, p =0.030), C (8 vs 5, p =0.042) and C+T raise (10.9 vs 5.0, p=0.003). At the multivariate analysis, only C+T increase was associated with improved TTP (p=0.005). T raise (21.0 vs 14.0, p=0.002) and C+T increase (21.0 vs 14.0, p=0.006) were correlated with improved OS but were not significant at multivariate analysis. Conclusion: C+T raise is an early predictor for everolimus efficacy for patients with mRCC. |
| تدمد: | 1932-6203 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::523e78cbd66b81c8587895207fa30148Test https://pubmed.ncbi.nlm.nih.gov/25885920Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....523e78cbd66b81c8587895207fa30148 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|